The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.
During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...
The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...
Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...
Opdivo Qvantig combines nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of the SC tissue. Opdivo was ...
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...
Opdivo Qvantig is a combination product of nivolumab coformulated with recombinant human hyaluronidase. This approval is for most previously approved adult, solid tumor Opdivo indications as ...
Opdivo and Opdivo Qvantig showed similar safety profiles. The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is ...
Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...
US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications: Princeton, New Jersey Monday, December 30, 2024, ...